title: Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
abstract: Opioid dependence is a growing problem. Methadone is an established agent for the treatment of opioid dependence, but there is a risk of this agent being abused, a potential for interaction with antiretroviral agents and a risk of cardiac toxicity. Another option is the partial mu-opioid receptor opioid agonist buprenorphine, which has been used successfully to manage opioid dependence. While the risk of abuse is lower than that for methadone, there is still a risk. The sublingual combination formulation of buprenorphine and the opioid receptor antagonist naloxone (buprenorphine/naxolone) is a newer agent with reduced abuse potential, and has been shown to have promising efficacy for opioid dependence. We describe the results of an observational study investigating the safety and efficacy of buprenorphine/naloxone in opioid-dependent patients. A total of 77 patients were included and were switched from buprenorphine to sublingual tables of buprenorphine/naloxone; the buprenorphine dosage was titrated to achieve good control of withdrawal symptoms. The prevalence of withdrawal symptoms, craving, constipation, cramps, insomnia, sexual activity, depression, sweating, distress, bone/joint pain and drowsiness were compared over the first 30 days of treatment (period 1) and the total 120-day study duration (period 2). The average buprenorphine/naloxone dose in period 1 was 7.3 mg/day and 12.7 mg/day in period 2. Most patients did not experience any withdrawal symptoms in either period 1 or period 2. Fewer than 20% of patients experienced any cravings over the 120-day study period. Importantly, the adverse effects observed were usually mild, with very few patients experiencing significant adverse effects. This study shows that buprenorphine/naloxone is an effective and well tolerated treatment for opioid withdrawal when the dosage is titrated to achieve good control of withdrawal symptoms. Switching from buprenorphine alone to buprenorphine/naloxone was possible with very little discomfort for the patient and effective retained patients in treatment.
authors.affiliation: U.O.C. Ser.T Cosenza Provincial Health Agency, Cosenza, Italy.
authors.forename: Fernanda
authors.initials: F
authors.lastname: Magnelli
authors.forename: Lorita
authors.initials: L
authors.lastname: Biondi
authors.forename: Roberto
authors.initials: R
authors.lastname: Calabria
authors.forename: Angelo
authors.initials: A
authors.lastname: Fiore
authors.forename: Eugenio
authors.initials: E
authors.lastname: Peluso
authors.forename: Domenico
authors.initials: D
authors.lastname: Vonella
authors.forename: Amerigo Giuseppe
authors.initials: AG
authors.lastname: Rota
mesh_terms: D000286:Administration, Sublingual; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D016739:Behavior, Addictive; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007558:Italy; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage* / Q000009:adverse effects; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000523:psychology; D015813:Substance Abuse Detection; D016320:Substance Abuse Treatment Centers; D015819:Substance Abuse, Intravenous / Q000175:diagnosis / Q000517:prevention & control; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000523:psychology; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D004338:Drug Combinations; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine
references.citation: J Pharmacol Exp Ther. 1988 Oct;247(1):47-53
references.pmid: 2459370
references.citation: Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37
references.pmid: 12738348
references.citation: Br J Nurs. 2009 Sep 10-23;18(16):998-1002
references.pmid: 19773693
references.citation: Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S59-77
references.pmid: 12738351
references.citation: Drug Alcohol Depend. 2000 Dec 22;61(1):85-94
references.pmid: 11064186
references.citation: Drug Alcohol Depend. 2007 Apr 17;88(1):75-8
references.pmid: 17055191
references.citation: Am J Psychiatry. 2007 May;164(5):797-803
references.pmid: 17475739
references.citation: Acta Neuropsychiatr. 2004 Oct;16(5):246-74
references.pmid: 26984437
references.citation: Arch Intern Med. 2007 Dec 10;167(22):2469-75
references.pmid: 18071169
references.citation: Int J Addict. 1978 Aug;13(6):855-62
references.pmid: 730402
references.citation: JAMA. 2008 Nov 5;300(17):2003-11
references.pmid: 18984887
references.citation: Addiction. 2005 Aug;100(8):1090-100
references.pmid: 16042639
references.citation: Cochrane Database Syst Rev. 2003;(2):CD002207
references.pmid: 12804429
references.citation: N Engl J Med. 2003 Sep 4;349(10):949-58
references.pmid: 12954743
references.citation: CNS Drugs. 2006;20(9):697-712
references.pmid: 16953647
references.citation: Drug Alcohol Rev. 2004 Sep;23(3):311-7
references.pmid: 15370011